Merck's ( NYSE: MRK) experimental antibody drug conjugate zilovertamab vedotin, in combination with standard of care, ...

(SMMT) stock rises as its lung cancer drug ivonescimab with chemotherapy hit the main goal in a Phase 3 trial for lung cancer ...

US FDA grants priority review status to Bayer’s sevabertinib to treat patients with HER2-mutant non-small cell lung cancer: Berlin Friday, May 30, 2025, 16:00 Hrs [IST] Bayer an ...

Findings from HERTHENA-Lung02 showed that the key secondary endpoint of overall survival did not meet statistical significance.

The therapy claims to be the first therapeutic agent to utilise molecularly defined biomarkers for precision-targeted HCC ...

Names like idarucizumab, levetiracetam and ustekinumab may look like words from Greek or Norse mythology, but they're chosen ...

Daiichi Sankyo & Merck voluntarily withdraws patritumab deruxtecan BLA to treat locally advanced or metastatic EGFR-mutated NSCLC from US FDA: Basking Ridge, New Jersey Friday, Ma ...

ATLANTA and BOSTON, May 28, 2025 (GLOBE NEWSWIRE) -- ABLi Therapeutics ("ABLi”), a biotechnology company developing ...

DZD8586 demonstrated significant anti-tumor efficacy in heavily pretreated chronic lymphocytic leukemia/small lymphocytic ...

TURKU, FI / ACCESS Newswire / May 27, 2025 / Faron Pharmaceuticals (HEL:FARON)(LSE:FARN) - New preclinical data published in Scientific Reports confirms CLEVER-1 inhibition by Bexmarilimab increases a ...

Avenzo gets FDA permission to proceed with Phase I/II trials of an EGFR/HER3 bispecific antibody and a CDK4 inhibitor in select solid tumors.